Cargando…
First-Line Immunotherapy with Check-Point Inhibitors: Prospective Assessment of Cognitive Function
SIMPLE SUMMARY: About 40% of people diagnosed with cancer are eligible for treatment with checkpoint inhibitors (CPIs). Little research has been conducted to understand whether CPIs affect cognitive function. Most research that has been conducted included patients who received both CPIs and chemothe...
Autores principales: | Myers, Jamie S., Parks, Adam C., Mahnken, Jonathan D., Young, Kate J., Pathak, Harsh B., Puri, Rajni V., Unrein, Amber, Switzer, Phyllis, Abdulateef, Yazan, Sullivan, Samantha, Walker, John F., Streeter, David, Burns, Jeffrey M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000599/ https://www.ncbi.nlm.nih.gov/pubmed/36900405 http://dx.doi.org/10.3390/cancers15051615 |
Ejemplares similares
-
The next generation of immunotherapy: keeping lung cancer in check
por: Somasundaram, Ashwin, et al.
Publicado: (2017) -
Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy
por: SEYA, Tsukasa, et al.
Publicado: (2018) -
Implementing a home-based virtual hypertension programme—a pilot feasibility study
por: Gupta, Aditi, et al.
Publicado: (2022) -
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
por: Ackley, James, et al.
Publicado: (2021) -
Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses
por: Wang, Ying, et al.
Publicado: (2019)